OTCM
VDRM
Market cap493kUSD
Jul 09, Last price
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-84.00%
IPO
-100.00%
Name
Viaderma Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ViaDerma, Inc., a specialty pharmaceutical enterprise based in the United States, focuses on both the development and commercialization of pharmaceutical products. It also licenses its proprietary technology to other companies within the pharmaceutical sector, addressing various therapeutic areas. The company's primary offering is Vitastem, a topical antibiotic containing tetracycline, effective for treating a broad spectrum of ailments such as cuts, scrapes, wounds, infections, burns, acne, psoriasis, eczema, and minor injuries. Beyond its established products, ViaDerma is dedicated to expanding its pipeline, with ongoing development in fields including advanced topical antibiotics, antifungal treatments for toenails, diabetic amputation recovery, general acne, psoriasis, eczema, burn care, anti-aging and wrinkle-reducing formulations, medical cannabis applications, male pattern baldness, skin cancer, erectile dysfunction, and pain management. Established in 2007, the company operated as Décor Products International, Inc. until its renaming to ViaDerma, Inc. in May 2014. Its corporate operations are directed from Marina Del Rey, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||